Disease activity parameters in axSpA patients at baseline and 6 and 12 months post-switch from originator adalimumab to adalimumab-AACF
| Disease activity parameters at baseline and after switching | Baseline (n = 28) | 6 months (n = 27) | P | 12 months (n = 27) | P |
|---|---|---|---|---|---|
| ASDAS-CRP | 1.56 (± 0.88) | 1.50 (± 0.82) | 0.732 | 1.26 (± 0.86) | 0.133 |
| ASDAS-ESR | 1.47 (± 0.93) | 1.57 (± 0.78) | 0.876 | 1.27 (± 0.87) | 0.979 |
| BASDAI | 1.30 (± 1.43) | 1.26 (± 1.63) | 0.176 | 0.99 (± 1.28) | 0.331 |
| CRP (mg/L) | 3.9 (1.9; 8.1) | 2.6 (1.8; 4.9) | 0.310 | 2.6 (1.63; 6.9) | 0.494 |
Data are presented as mean (± standard deviation) or median (interquartile range); statistical significance was considered when P < 0.05. axSpA: axial spondyloarthritis; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-reactive protein; ASDAS-ESR: Ankylosing Spondylitis Disease Activity Score-erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index